论文部分内容阅读
采用DP和NP方案治疗蒽环类耐药的晚期乳腺癌73例。DP方案:多西紫杉醇75mg/m2,静脉滴入,d1;顺铂30mg/m2,静脉滴入,d2~d4;NP方案:长春瑞滨25mg/m2,静脉推注,d1、d5;顺铂30mg/m2,静脉滴入,d2~d4;上述2个方案每3周为1个周期。结果为DP方案的总有效率为51·3%(19/37),中位疾病进展时间(TTP)8·5个月,中位生存时间19个月,1年生存率60·7%;NP方案的总有效率为41·6%(15/36),中位TTP7个月,中位生存时间16个月,1年生存率56·6%。两组方案的主要不良反应为骨髓抑制及胃肠道反应。初步研究结果提示,两组方案对于蒽环类耐药的晚期乳腺癌患者均有较好疗效,不良反应可耐受,其近期疗效差异无统计学意义,P=0·407。
Treatment of 73 cases of anthracycline-resistant advanced breast cancer with DP and NP regimens. DP regimen: docetaxel 75mg / m2, intravenous infusion, d1; cisplatin 30mg / m2, intravenous infusion, d2 ~ d4; NP regimen: vinorelbine 25mg / m2, intravenous injection, d1, d5; 30mg / m2, intravenous infusion, d2 ~ d4; the two programs every 3 weeks for a cycle. The results showed that the total effective rate of DP was 51.3% (19/37), the median time to progression of disease (TTP) was 8.5 months, the median survival time was 19 months and the one-year survival rate was 60.7%. The total effective rate of NP was 41.6% (15/36). The median duration of TTP was 7 months, the median survival time was 16 months, and the 1-year survival rate was 56.6%. The main adverse reactions of the two groups were myelosuppression and gastrointestinal reactions. Preliminary results suggest that the two groups of programs for anthracycline-resistant patients with advanced breast cancer have a good effect, adverse reactions are tolerable, the short-term efficacy was no significant difference (P = 0 · 407).